PMID- 31969412
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20220122
IS  - 1757-790X (Electronic)
IS  - 1757-790X (Linking)
VI  - 13
IP  - 1
DP  - 2020 Jan 21
TI  - Follicular lymphoma presenting as hyperleucocytosis.
LID - 10.1136/bcr-2019-233007 [doi]
LID - e233007
AB  - Follicular lymphoma is the second most common subtype of non-Hodgkin's lymphoma 
      affecting adults. Clinically, follicular lymphoma is generally indolent, most 
      often presenting as a painless peripheral lymphadenopathy; however, a 
      leucocytosis at presentation is exceedingly rare. We present the case of a 
      63-year-old woman with follicular lymphoma with a presenting hyperleucocytosis at 
      diagnosis of 1 327 000/muL demonstrated on laboratory analysis work while 
      hospitalised for progressive weakness. fluorescence in situ hybridization (FISH) 
      panel was consistent with follicular lymphoma, which was positive for B-cell 
      leukaemia/lymphoma 2 and negative for MYC Proto-Oncogene. Cytoreduction with 
      rituximab-containing therapy was initiated, with the patient ultimately expiring. 
      A leukaemic phase at presentation appears to be associated with poor outcome. The 
      findings from our case, in addition to others, have potential implications in 
      regard to prognostic utility. The current prognostic tool used to estimate 
      overall survival for follicular lymphoma, Follicular Lymphoma International 
      Prognostic Index, does not take leucocytosis into account.
CI  - (c) BMJ Publishing Group Limited 2020. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Worth, Heidi A
AU  - Worth HA
AD  - Department of Medicine, University of Tennessee Knoxville, Knoxville, Tennessee, 
      USA hworth@utmck.edu.
FAU - Cochrane, Katherine
AU  - Cochrane K
AD  - Department of Pathology, University of Tennessee Knoxville, Knoxville, Tennessee, 
      USA.
FAU - Aljadir, David
AU  - Aljadir D
AD  - Department of Pathology, University of Tennessee Knoxville, Knoxville, Tennessee, 
      USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200121
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Fatal Outcome
MH  - Female
MH  - Humans
MH  - Leukocytosis/*drug therapy/*etiology
MH  - Lymphoma, Follicular/*complications/*drug therapy
MH  - Middle Aged
MH  - Proto-Oncogene Mas
PMC - PMC7035848
OTO - NOTNLM
OT  - chemotherapy
OT  - haematology (drugs and medicines)
OT  - haematology (incl blood transfusion)
OT  - malignant disease and immunosuppression
OT  - oncology
COIS- Competing interests: None declared.
EDAT- 2020/01/24 06:00
MHDA- 2020/09/12 06:00
PMCR- 2022/01/21
CRDT- 2020/01/24 06:00
PHST- 2020/01/24 06:00 [entrez]
PHST- 2020/01/24 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2022/01/21 00:00 [pmc-release]
AID - 13/1/e233007 [pii]
AID - bcr-2019-233007 [pii]
AID - 10.1136/bcr-2019-233007 [doi]
PST - epublish
SO  - BMJ Case Rep. 2020 Jan 21;13(1):e233007. doi: 10.1136/bcr-2019-233007.